0001641172-25-023575.txt : 20250813 0001641172-25-023575.hdr.sgml : 20250813 20250813170543 ACCESSION NUMBER: 0001641172-25-023575 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250813 DATE AS OF CHANGE: 20250813 EFFECTIVENESS DATE: 20250813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Qualigen Therapeutics, Inc. CENTRAL INDEX KEY: 0001460702 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 263474527 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-554645 FILM NUMBER: 251212742 BUSINESS ADDRESS: STREET 1: 2042 CORTE DEL NOGAL STREET 2: CARLSBAD CITY: CALIFORNIA STATE: CA ZIP: 92011 BUSINESS PHONE: (760) 918-9165 MAIL ADDRESS: STREET 1: 2042 CORTE DEL NOGAL STREET 2: CARLSBAD CITY: CALIFORNIA STATE: CA ZIP: 92011 FORMER COMPANY: FORMER CONFORMED NAME: RITTER PHARMACEUTICALS INC DATE OF NAME CHANGE: 20090402 D 1 primary_doc.xml X0708 D LIVE 0001460702 Qualigen Therapeutics, Inc. 5857 OWENS AVENUE SUITE 300 CARLSBAD CA CALIFORNIA 92008 (760) 452-8111 DELAWARE None RITTER PHARMACEUTICALS INC Corporation true Kevin Richardson II 5857 Owens Avenue Suite 300 Carlsbad CA CALIFORNIA 92008 Director Campbell Becher 5857 Owens Avenue Suite 300 Carlsbad CA CALIFORNIA 92008 Executive Officer Director Braeden Lichti 5857 Owens Avenue Suite 300 Carlsbad CA CALIFORNIA 92008 Director Robert B. Lim 5857 Owens Avenue Suite 300 Carlsbad CA CALIFORNIA 92008 Director Cody Price 5857 Owens Avenue Suite 300 Carlsbad CA CALIFORNIA 92008 Director Biotechnology Decline to Disclose 06b false 2025-07-28 false true true Convertible Preferred Stock can convert to underlying shares of Common Stock false 0 Univest Securities LLC 000036105 None None 75 ROCKEFELLER PLAZA SUITE 1838 NEW YORK NY NEW YORK 10019 AZ ARIZONA MN MINNESOTA NE NEBRASKA NV NEVADA NY NEW YORK UT UTAH false 4500000 4500000 0 false 14 0 true 0 true No sales commission or finder's fees 0 true false Qualigen Therapeutics, Inc. /s/ Kevin Richardson II Kevin Richardson II Interim Chief Executive Officer and Chief Financial Officer 2025-08-13